fashion -WSS

fashion

author：leisure time 2025-09-30 17:43:37 - browse：33923

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Wegovy leads to weight loss. Can it treat depression, too?

hotspot

WSS

Anavex keeps shifting the goalposts in its clinical trials

Investment in vaccine development is lagging, report finds

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

South Korea throws huge K

Humana’s losses in Medicare Advantage tank its stock

FDA panel issues narrow recommendation for Covid vaccine booster doses

Wikipedia

fashion

Wikipedia

United colonoscopy coverage change 'may cost lives,' doctors say

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Pancreatic cancer early detection could be helped by AI

In age of alternative facts, a scholarly course on calling out crap

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Anesthesiologist group: stop taking Ozempic before surgery

Merck, Johnson & Johnson CEOs will testify on high drug prices

Walensky prepares to leave CDC — and Congress — behind

Police still searching for prisoner who escaped from NYC hospital

explore

Investment in vaccine development is lagging, report finds

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

For Cytokinetics, FDA rejection of heart drug would help, not hinder

White House pharmacy plagued with problems, investigation finds

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Zyn nicotine pouches become unlikely player in latest culture war

focus

hotspot

hotspot

hotspot